Professor, Medicine, UCLA School of Medicine
Hematology
Dr. Antoni B. Ribas, MD
|
|
Give Review
Antoni B. Ribas works in the field of Hematology. He received 1 awards: "Elected Member". Antoni Ribas is a published doctor and has 53 publications published. The lastest was: 'Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma.
- Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.
- Gauging the Long-Term Benefits of Ipilimumab in Melanoma.
- Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
- The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
- PD-1 blockade induces responses by inhibiting adaptive immune resistance.
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib.
- Adjuvant Vaccine Immunotherapy of Resected, Clinically Node-Negative Melanoma: Long-term Outcome and Impact of HLA Class I Antigen Expression on Overall Survival.
- Southwest Oncology Group S0008: A Phase III Trial of High-Dose Interferon Alfa-2b Versus Cisplatin, Vinblastine, and Dacarbazine DTIC, Plus Interleukin-2 and Interfero...
- The Future of Cancer Therapy: Selecting Patients Likely to Respond to PD1/L1 Blockade.
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma.
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma.
- T-cell immunotherapy: looking forward.
- Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
- HSV-sr39TK positron emission tomography and suicide gene elimination of human hematopoietic stem cells and their progeny in humanized mice.
- Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma.
- Combining Targeted Therapy With Immunotherapy in BRAF-Mutant Melanoma: Promise and Challenges.
- Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function.
- Bilateral Subfoveal Neurosensory Retinal Detachment Associated With MEK Inhibitor Use for Metastatic Cancer.
- Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients.
- Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence.
- The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics.
- COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors.
- New Drug Targets in Metastatic Melanoma.
- Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma.
- Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
- BRAF-targeted therapy and immune responses to melanoma.
- Combining cancer immunotherapy and targeted therapy.
- Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma.
- Impact of MET expression on outcome in BRAF(V600E/K) advanced melanoma.
- Meeting report from the Society for Melanoma Research 2012 Congress, Hollywood, California.
- Polymer nanofiber-embedded microchips for detection, isolation, and molecular analysis of single circulating melanoma cells.
- Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy.
- Allelic Exclusion and Peripheral Reconstitution by TCR Transgenic T Cells Arising From Transduced Human Hematopoietic Stem/Progenitor Cells.
- Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor.
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma.
- BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy.
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.
- Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death.
- Tumor Immunotherapy Directed at PD-1.
- Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors.
- The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms.
- Marked, Homogeneous, and Early 18FFluorodeoxyglucose-Positron Emission Tomography Responses to Vemurafenib in BRAF-Mutant Advanced Melanoma.
- Phase I/II trial of tremelimumab in patients with metastatic melanoma.
- Novel insights/translational implication from the emerging biology of melanoma.
- Natural killer T cells in advanced melanoma patients treated with tremelimumab.
- Chemical dissection of the cell cycle: probes for cell biology and anti-cancer drug development.
- A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States.
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.
- Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?
Schools
Universidad De Barcelona Facultad De Medicina
Conditions Treated
- Acute Leukemia
- Anemia
- Burkitt's Lymphoma
- Central Nervous System Lymphoma
- View All
Doctors Specialties
- Hematology
Accepted Insurances
Awards
- Elected Member
Education
-
UCLA Medical Center -
Universidad de Barcelona Faculty of Medicine
Hospital
-
Ronald Reagan UCLA Medical Center -
Santa Monica-UCLA Medical Center and Orthopaedic Hospital
Drug Facts
| NPI NUMBER | 1730109331 | |
| NPPES Provider LastName | RIBAS | |
| NPPES Provider FirstName | ANTONI | |
| NPPES Provider ZIPCode | 90095 | |
| NPPES Provider State | CA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 21.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1730109331 |
| Last Name Of The Provider | RIBAS |
| First Name Of The Provider | ANTONI |
| View All |
Similar Doctors
|
|
Dr. Kanchana S. Anand, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ani Balmanoukian, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cage S. Johnson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vinod Pullarkat, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Youram C. Nassir, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard S. Finn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary M. Ichiuji, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert V. Pierre, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary C. Territo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Teresa Dubernet, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mintallah Haider, MD |
|
|
Dr. Gino K. In, MD |
|
|
Nanette C. Fong, NP |
|
|
Lawrence K. Low |